Editas Medicine (EDIT) reported a loss of 55 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 39 cents. The company had incurred a loss of 23 cents per share in the year-ago quarter.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $30.6 million in the reported quarter, down 49$60 million reported in the year-ago qua ...